JP2008523022A - リン化合物の吸収のための経口組成物 - Google Patents
リン化合物の吸収のための経口組成物 Download PDFInfo
- Publication number
- JP2008523022A JP2008523022A JP2007544881A JP2007544881A JP2008523022A JP 2008523022 A JP2008523022 A JP 2008523022A JP 2007544881 A JP2007544881 A JP 2007544881A JP 2007544881 A JP2007544881 A JP 2007544881A JP 2008523022 A JP2008523022 A JP 2008523022A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- phosphorus
- medicament
- pharmaceutically acceptable
- binding agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、唾液および他の胃分泌物がかなりの量のリンを含むという発見に基づく。特に、唾液は、リンの主要な供給源(該リンは次いで、身体中で再循環される)であると考えられる。
本発明の目的のために、経口組成物は、被験者に経口経路によって投与することができるいずれかの組成物であると企図する。
徐放性水酸化マグネシウム:250mg、
徐放性水酸化アルミニウム:250mg、
スクロース粉末、デンプン、ソルビトール、マンニトール、芳香剤、サッカリンナトリウム、ステアリン酸マグネシウム。
唾液中のリンの測定
a)透析処置を受けている尿毒症の患者
週に3回、ポリスルホン透析器を用いて定期的に重曹透析(HD)を受けている68尿毒症患者(47男性および21女性、年齢61.6±9.4)、および同年齢の30コントロールの健康被験者を含んだ。
−血中Ca 8.73 mg/dl(幾何学的平均値)−95% CI、8.49〜8.98;
−唾液中Ca 7.21 mg/dl(幾何学的平均値)−95% CI、6.58〜7.91;
−血中P 5.73±1.31 mg/dl(平均値)−95% CI、5.41〜6.04;
−唾液中P 30.27 mg/dl(幾何学的平均値)−95% CI、26.50〜34.58;
−PTH 5.73±143.63 pg/ml(平均値)−95% CI、110.57〜167.69;
−唾液中P 30.27 mg/ml(幾何平均値)−95% CI、26.50〜34.58。
−唾液中P 12.66±5.25 mg/dl(平均値)−95% CI、10.58〜14.73。
保存療法下での110患者(59男性および51女性、年齢65;17〜90)は、メッシーナ(Messina, イタリア国)におけるパラルド病院(Papardo Hospital)での透析ユニットでランダムに選別した。リンアッセイを妨害することが知られる薬物を用いた処置下にある患者を排除するように、注意を払った。治験プロトコールは、血中クレアチニンアッセイおよび血中リンアッセイ、並びに唾液中リンアッセイを含んだ。終夜の絶食後に、血液(4ml)および唾液(2ml)の試料を午前8時に採取した。糸球体濾過率(GFR)を、下記のMDRD式に従って算出した。
[GFR (ml/分/1.73 m2) = 186×(血中クレアチニン)-1.154×(年齢)−0.203×(女性の場合は、0.742)]
表1
110被験者における臨床データ
唾液中のPを予測するための後退選択段階式重回帰モデル;最終モデル
キトサン製剤
リン酸塩の量を分離した中および低−粘性のキトサンを、1次元スペクトル取得を有する500MHzの高分解能31P−NMR(HR−NMR)によって300°Kで測定した。
a)低−と中−粘性のキトサン(フルカ社製, カタログ番号50494およびカタログ番号28191)および、PBS(リン酸塩緩衝化生理食塩水−シグマ社製)を有する異なる濃度の溶液との相互作用を研究し、そして同じ実験条件下での純粋なPBSおよびキトサン含有PBSの間でのリン酸塩の量の差違を比較し;
b)文献(チャング(Yong Zhang)およびチャング(M. Zhang)による, J. Biomed. Mater. Res., 2002, Dec. 5, 5, 62(3): 378-86)に従って、PBSと異なる濃度の中粘性キトサン溶液との相互作用を研究した。
低−および中−粘性のキトサンの0.2、1.0、および1.5gを、PBS(10ml)に加えて、2、10、および15%p/vのキトサン溶液を得た。
中−粘性キトサンのそれぞれ1.0および2.0gを0.2M 酢酸(10ml)中に溶解して、10および20%p/vのキトサン溶液を得た。その後に、該得た溶液を50℃で約2時間撹拌して、均一な高分子溶液を得た。該溶液をろ過して空気泡を除いた。該ろ過溶液にPBS(0.0931g)を加えて、そしてこれを−20℃で凍結して固体を分離した。液相を、NMR分析のために除去した。
Claims (16)
- リン化合物結合性剤、並びに少なくとも1つのその医薬的に許容し得るビヒクルおよび/または賦形剤を含有する、連続的な徐放性の経口医薬組成物。
- 該組成物は、丸剤、トローチ剤、錠剤、カプセル剤、粉末状組成物、液剤、懸濁剤、乳剤、および菓子からなる群から選ばれる、請求項1記載の組成物。
- 該リン化合物結合剤は、リン酸塩結合性高分子、ランタンの医薬的に許容し得る塩、マグネシウムの医薬的に許容し得る塩、カルシウムの医薬的に許容し得る塩、ケト酸の医薬的に許容し得る塩、医薬的に許容し得るアニオン性イオン交換樹脂、医薬的に許容し得るリン結合性多糖類からなる群から選ばれる、請求項1または2のいずれかに記載の組成物。
- 該リン結合性剤は、ポリアリルアミン塩酸塩、ポリアリルアミン炭酸塩、炭酸ランタン、水酸化アルミニウム、酢酸マグネシウム、炭酸マグネシウム、炭酸カルシウム、酢酸カルシウム、クエン酸カルシウム、アルギン酸カルシウム、スチレン−ジビニルベンゼンアニオン交換樹脂、およびキトサンからなる群から選ばれる、請求項3記載の組成物。
- 該リン結合性剤はリン酸塩結合剤である、請求項4記載の組成物。
- 該組成物は、咀嚼錠、サッシェ、シロップ、口腔洗浄薬、チューインガム、グミキャンディ、吸い型錠剤、および吸い型キャンディからなる群から選ばれる、請求項1〜5のいずれか1つに記載の組成物。
- 該組成物は、該組成物の単位用量の吸収能力の枯渇をシグナル伝達するための検出手段を供する、請求項1〜6のいずれか1つに記載の組成物。
- 該検出手段は該組成物中に含まれる、請求項7記載の組成物。
- 絶食期間中に高リン酸塩血症を処置するための医薬の製造における、リン結合性剤の使用。
- 該医薬は、腎疾患、腎不全、上皮小体低下症、骨粗鬆症、およびアテローム硬化症からなる群から選ばれる疾患において使用する、請求項9記載の使用。
- 該医薬は、透析処置を受けている尿毒症患者において使用する、請求項10記載の使用。
- 該医薬は、保存療法下の慢性腎不全の患者において使用する、請求項10記載の使用。
- 該医薬は、該結合性剤の枯渇まで口腔中に保持される、請求項9〜12のいずれか1つに記載の使用。
- 該医薬は、該結合性剤の部分的な枯渇まで口腔中に保持され、その後に該医薬は嚥下される、請求項9〜12のいずれか1つに記載の使用。
- 該医薬は少なくとも1つの治療ユニットを含み、該治療ユニットは直ちに嚥下される該結合性剤の少なくとも1つの第1の単位用量、および該結合性剤の枯渇まで口腔中に保持される該結合性剤の少なくとも1つの第2の単位用量を含む、請求項9〜12のいずれか1つに記載の使用。
- 高リン酸塩血症の処置のための医薬の製造における、キトサンの使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITME2004A000015 | 2004-12-07 | ||
IT000015A ITME20040015A1 (it) | 2004-12-07 | 2004-12-07 | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
PCT/EP2005/056289 WO2006061336A2 (en) | 2004-12-07 | 2005-11-29 | Oral compositions for absorption of phosphorus compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008523022A true JP2008523022A (ja) | 2008-07-03 |
JP5049135B2 JP5049135B2 (ja) | 2012-10-17 |
Family
ID=36035790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007544881A Expired - Fee Related JP5049135B2 (ja) | 2004-12-07 | 2005-11-29 | リン化合物の吸収のための経口組成物 |
Country Status (21)
Country | Link |
---|---|
US (4) | US7815898B2 (ja) |
EP (1) | EP1827386B1 (ja) |
JP (1) | JP5049135B2 (ja) |
KR (1) | KR101283820B1 (ja) |
CN (1) | CN101068535A (ja) |
AT (1) | ATE481091T1 (ja) |
BR (1) | BRPI0518517A2 (ja) |
CA (1) | CA2587924C (ja) |
CY (1) | CY1110985T1 (ja) |
DE (1) | DE602005023648D1 (ja) |
DK (1) | DK1827386T3 (ja) |
ES (1) | ES2352957T3 (ja) |
HR (1) | HRP20100653T1 (ja) |
IT (1) | ITME20040015A1 (ja) |
MX (1) | MX2007006704A (ja) |
PL (1) | PL1827386T3 (ja) |
PT (1) | PT1827386E (ja) |
RS (1) | RS51507B (ja) |
RU (1) | RU2392926C2 (ja) |
SI (1) | SI1827386T1 (ja) |
WO (1) | WO2006061336A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539768A (ja) * | 2010-10-13 | 2013-10-28 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 簡単な投与のためのリン酸塩結合剤製剤 |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
CA2620406A1 (en) | 2005-09-02 | 2007-03-08 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
ITRM20060204A1 (it) * | 2006-04-10 | 2007-10-11 | Vincenzo Savica | Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche |
JP2009542653A (ja) * | 2006-07-05 | 2009-12-03 | ジェンザイム コーポレーション | リン酸塩過剰血症のための鉄(ii)含有治療剤 |
US7943597B2 (en) | 2008-04-08 | 2011-05-17 | Cypress Pharmaceutical, Inc. | Phosphate-binding chitosan and uses thereof |
AU2008354325A1 (en) * | 2008-04-08 | 2009-10-15 | Cypress Pharmaceutical, Inc. | Phosphate-binding chitosan and uses thereof |
US8877907B2 (en) | 2010-06-07 | 2014-11-04 | The Johns Hopkins University | Molecularly imprinted polymers |
US9314523B2 (en) | 2010-09-21 | 2016-04-19 | Elwha Llc | Ingestible salt grabber |
US9402808B2 (en) | 2011-01-19 | 2016-08-02 | Panacea Biotec Limited | Liquid oral composition of lanthanum salts |
EP2699099A1 (en) * | 2011-04-20 | 2014-02-26 | Gumlink A/S | Chewing gum comprising chitosan for use in reduction of the level of free phosphorus compounds in the digestive juice |
WO2012143008A1 (en) | 2011-04-20 | 2012-10-26 | Gumlink A/S | Reduction of the level of free phosphorus compounds in the digestive juice |
ES2607986T3 (es) * | 2011-06-08 | 2017-04-05 | Kai Pharmaceuticals, Inc. | Agentes terapéuticos para regular el fósforo en suero |
WO2014039477A1 (en) * | 2012-09-04 | 2014-03-13 | The Board Of Regents Of The University Of Texas System | Citrate-rich calcium-magnesium supplement and uses thereof |
WO2014166545A1 (en) | 2013-04-12 | 2014-10-16 | Cm&D Pharma Ltd | Compositions comprising a mixture of elastomers and chitosan and use thereof for treating disorders of phosphorous mineral metabolism |
EP3287133B1 (en) | 2013-06-05 | 2019-04-17 | Tricida Inc. | Proton-binding polymers for oral administration |
EP2818176A1 (en) | 2013-06-27 | 2014-12-31 | Virbac | Composition for the treatment of progressive renal diseases |
CN103536977A (zh) * | 2013-11-04 | 2014-01-29 | 于杰 | 血液灌流器 |
US9744128B2 (en) | 2014-06-05 | 2017-08-29 | Mastix LLC | Method for manufacturing medicated chewing gum without cooling |
JP6903576B2 (ja) | 2014-12-10 | 2021-07-14 | トリシダ・インコーポレイテッドTricida, Inc. | 経口投与用プロトン結合ポリマー |
CN109414453B (zh) | 2016-05-06 | 2023-02-17 | 特里赛达公司 | 用于治疗酸碱失衡的组合物 |
US10765658B2 (en) | 2016-06-22 | 2020-09-08 | Mastix LLC | Oral compositions delivering therapeutically effective amounts of cannabinoids |
US11266684B2 (en) | 2017-11-03 | 2022-03-08 | Tricida, Inc. | Compositions for and method of treating acid-base disorders |
TW201940175A (zh) * | 2017-11-29 | 2019-10-16 | 世展科技股份有限公司 | 磷結合方法 |
US11273123B2 (en) | 2018-07-18 | 2022-03-15 | USpharma Ltd | Chewable pharmaceutical dosage forms |
CN109528764B (zh) * | 2018-09-30 | 2021-04-06 | 北京市中关村医院 | 一种凝胶基层状无机物磷结合剂及其制备方法和用途 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61161216A (ja) * | 1985-01-11 | 1986-07-21 | Teijin Ltd | キトサン類を用いた徐放性医薬品組成物 |
JPS62132830A (ja) * | 1985-12-05 | 1987-06-16 | Teijin Ltd | 徐放性医薬品組成物 |
JPS63310833A (ja) * | 1987-06-10 | 1988-12-19 | Nippon Medical Supply Corp | リン吸着カプセル |
JPH05213762A (ja) * | 1992-01-31 | 1993-08-24 | Suzuyo Kk | リン吸着剤 |
WO2003059082A1 (en) * | 2002-01-16 | 2003-07-24 | Cadbury Adams Usa Llc. | Center-filled chewing gum containing calcium |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3818807A (en) * | 1972-12-06 | 1974-06-25 | Eng Concrete Placer Inc | Slurry pump piston seal |
US4181718A (en) * | 1975-12-29 | 1980-01-01 | Mason Norbert S | Polyanion-stabilized aluminum hydrogels |
US4163777A (en) | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
US4163177A (en) * | 1977-10-17 | 1979-07-31 | Ward Derrick A | Oscillation generator providing oscillations of varying amplitude |
US4160820A (en) * | 1977-11-28 | 1979-07-10 | General Mills, Inc. | Plaque inhibiting composition and method |
US4515769A (en) * | 1981-12-01 | 1985-05-07 | Borden, Inc. | Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same |
US4386106A (en) * | 1981-12-01 | 1983-05-31 | Borden, Inc. | Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition |
US4512968A (en) * | 1982-11-30 | 1985-04-23 | Lion Corporation | Oral compositions |
EP0187703B1 (en) * | 1985-01-11 | 1992-08-05 | Teijin Limited | Sustained release preparation |
DE3936319C3 (de) * | 1989-11-01 | 1997-05-07 | Bartz Volker | Phosphatbinder zur oralen Verabreichung |
US5030459A (en) * | 1989-11-07 | 1991-07-09 | Warner-Lambert Company | High impact mint flavor for high base chewing gum |
US5496545A (en) * | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
GB9506126D0 (en) * | 1995-03-25 | 1995-05-10 | Johnson Matthey Plc | Pharmaceutical composition and method |
ES2162658T3 (es) * | 1996-03-05 | 2002-01-01 | Mitsubishi Chem Corp | Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia. |
IE980990A1 (en) * | 1998-11-27 | 2000-05-31 | Fuisz Internat Ltd | Composition and Method for Medicated Chewing Gum Delivery System |
DE19917705C1 (de) | 1999-04-20 | 2000-12-28 | Vitasyn Gmbh | Mittel zur Therapie von Hyperphosphatämie |
US6645535B2 (en) * | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
FI121528B (fi) * | 2000-10-30 | 2010-12-31 | Biohit Oyj | Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa |
US20030072841A1 (en) * | 2001-03-19 | 2003-04-17 | The Procter & Gamble Campany | Polybutene containing chewing gum and confection |
ITMI20012320A1 (it) * | 2001-11-06 | 2003-05-06 | Perfetti Van Melle Spa | Composizioni orali solide anti-tartaro e anti-placca batterica, utilicome coadiuvanti nell'igiene odonto-stomatologica |
IL162823A0 (en) * | 2002-01-03 | 2005-11-20 | Yissum Res Dev Co | Edible compositions capable of removing oral biofilm |
SE0302947D0 (sv) * | 2003-01-24 | 2003-11-07 | Magle Ab | A composition material for transmucosal delivery |
EP2792363B1 (en) * | 2003-08-26 | 2016-06-29 | Shire Biopharmaceuticals Holdings Ireland Limited | Pharmaceutical formulation comprising lanthanum compounds |
US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
US8323683B2 (en) * | 2005-05-18 | 2012-12-04 | Mcneil-Ppc, Inc. | Flavoring of drug-containing chewing gums |
US20070207206A1 (en) * | 2006-03-02 | 2007-09-06 | Rice Bronwyn C | Chewable pain formula |
-
2004
- 2004-12-07 IT IT000015A patent/ITME20040015A1/it unknown
-
2005
- 2005-11-29 PT PT05810997T patent/PT1827386E/pt unknown
- 2005-11-29 PL PL05810997T patent/PL1827386T3/pl unknown
- 2005-11-29 ES ES05810997T patent/ES2352957T3/es active Active
- 2005-11-29 US US11/792,047 patent/US7815898B2/en not_active Expired - Fee Related
- 2005-11-29 RU RU2007125702/15A patent/RU2392926C2/ru not_active IP Right Cessation
- 2005-11-29 MX MX2007006704A patent/MX2007006704A/es active IP Right Grant
- 2005-11-29 DE DE602005023648T patent/DE602005023648D1/de active Active
- 2005-11-29 EP EP05810997A patent/EP1827386B1/en active Active
- 2005-11-29 JP JP2007544881A patent/JP5049135B2/ja not_active Expired - Fee Related
- 2005-11-29 KR KR1020077012746A patent/KR101283820B1/ko not_active IP Right Cessation
- 2005-11-29 WO PCT/EP2005/056289 patent/WO2006061336A2/en active Application Filing
- 2005-11-29 BR BRPI0518517-3A patent/BRPI0518517A2/pt not_active IP Right Cessation
- 2005-11-29 CN CNA2005800414580A patent/CN101068535A/zh active Pending
- 2005-11-29 AT AT05810997T patent/ATE481091T1/de active
- 2005-11-29 DK DK05810997.6T patent/DK1827386T3/da active
- 2005-11-29 RS RSP-2010/0513A patent/RS51507B/en unknown
- 2005-11-29 CA CA2587924A patent/CA2587924C/en not_active Expired - Fee Related
- 2005-11-29 SI SI200531182T patent/SI1827386T1/sl unknown
-
2010
- 2010-08-23 US US12/861,539 patent/US20100316578A1/en not_active Abandoned
- 2010-09-16 US US12/883,498 patent/US8518379B2/en not_active Expired - Fee Related
- 2010-11-29 HR HR20100653T patent/HRP20100653T1/hr unknown
- 2010-12-10 CY CY20101101144T patent/CY1110985T1/el unknown
-
2014
- 2014-08-18 US US14/462,038 patent/US20140356297A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61161216A (ja) * | 1985-01-11 | 1986-07-21 | Teijin Ltd | キトサン類を用いた徐放性医薬品組成物 |
JPS62132830A (ja) * | 1985-12-05 | 1987-06-16 | Teijin Ltd | 徐放性医薬品組成物 |
JPS63310833A (ja) * | 1987-06-10 | 1988-12-19 | Nippon Medical Supply Corp | リン吸着カプセル |
JPH05213762A (ja) * | 1992-01-31 | 1993-08-24 | Suzuyo Kk | リン吸着剤 |
WO2003059082A1 (en) * | 2002-01-16 | 2003-07-24 | Cadbury Adams Usa Llc. | Center-filled chewing gum containing calcium |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013539768A (ja) * | 2010-10-13 | 2013-10-28 | フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 簡単な投与のためのリン酸塩結合剤製剤 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0518517A2 (pt) | 2008-11-25 |
RS51507B (en) | 2011-06-30 |
ITME20040015A1 (it) | 2005-03-07 |
CN101068535A (zh) | 2007-11-07 |
US20100316578A1 (en) | 2010-12-16 |
WO2006061336A2 (en) | 2006-06-15 |
ES2352957T3 (es) | 2011-02-24 |
WO2006061336A3 (en) | 2006-09-14 |
US20080125394A1 (en) | 2008-05-29 |
EP1827386B1 (en) | 2010-09-15 |
PT1827386E (pt) | 2010-12-03 |
ATE481091T1 (de) | 2010-10-15 |
HRP20100653T1 (hr) | 2011-01-31 |
CA2587924C (en) | 2013-08-20 |
US20110002858A1 (en) | 2011-01-06 |
SI1827386T1 (sl) | 2011-01-31 |
US20140356297A1 (en) | 2014-12-04 |
US7815898B2 (en) | 2010-10-19 |
CY1110985T1 (el) | 2015-06-11 |
RU2392926C2 (ru) | 2010-06-27 |
PL1827386T3 (pl) | 2011-05-31 |
DK1827386T3 (da) | 2011-07-11 |
EP1827386A2 (en) | 2007-09-05 |
KR20070090904A (ko) | 2007-09-06 |
MX2007006704A (es) | 2008-01-16 |
RU2007125702A (ru) | 2009-01-20 |
KR101283820B1 (ko) | 2013-07-15 |
DE602005023648D1 (de) | 2010-10-28 |
US8518379B2 (en) | 2013-08-27 |
CA2587924A1 (en) | 2006-06-15 |
JP5049135B2 (ja) | 2012-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5049135B2 (ja) | リン化合物の吸収のための経口組成物 | |
CA2658465C (en) | Liquid compositions of calcium acetate | |
DK148344B (da) | Fremgangsmaade til fremstilling af et farmaceutisk praeparat med forlaenget afgivelse af aktivt stof | |
JPH05194234A (ja) | ジデオキシプリンヌクレオシドの改良された経口投与処方物 | |
JP2008534523A (ja) | メトホルミンの経口経粘膜送達のための組成物 | |
US20030108605A1 (en) | Mineral supplement | |
WO2010005965A1 (en) | Colonic purgative formulations and methods of using the same | |
CN115089618B (zh) | 一种用于防治骨质疏松的药物组合物及其制备方法 | |
CN114832020B (zh) | 一种用于防治儿童发育障碍的药物组合物及其制备方法 | |
AU2013202958B2 (en) | Liquid Compositions of Calcium Acetate | |
AU614962C (en) | An antacid composition | |
DK169122B1 (da) | Antacidpræparat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080512 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080512 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110909 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110916 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120611 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120703 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120720 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150727 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |